FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

The FDA approved Zolinza capsules for the treatment of cutaneous T-cell lymphomalymphoma, a lymphoma that affects the skin. The FDA, in a news release, said the drug was approved to use when the disease worsens, is persistent or returns after treatment with other drugs.

About 3 in 1 million people, mainly middle-aged men, are diagnosed with CTCL each year, the FDA said.

The FDA said it approved Zolinza as part of its Orphan Drug program, which offers companies financial incentives to develop medicines for diseases and conditions affecting fewer than 200,000 people in the United States a year.

Zolinza is manufactured by Pantheon Inc. for Merck & Co. Inc., the FDA said.

Copyright 2006 by United Press International

Explore further: Merck, Iowa firm sign Ebola vaccine licensing deal (Update)

add to favorites email to friend print save as pdf

Related Stories

Algorithm, not live committee, performs author ranking

24 minutes ago

Thousands of authors' works enter the public domain each year, but only a small number of them end up being widely available. So how to choose the ones taking center-stage? And how well can a machine-learning ...

Senators get no clear answers on air bag safety

11 hours ago

There were apologies and long-winded explanations, but after nearly four hours of testimony about exploding air bags, senators never got a clear answer to the question most people have: whether or not their ...

Nicaragua: Studies say canal impact to be minimal

11 hours ago

Officials said Thursday that studies have determined a $40 billion inter-oceanic canal across Nicaragua will have minimal impact on the environment and society, and construction is to begin next month.

Recommended for you

Powdered measles vaccine found safe in early clinical trials

8 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.